Your browser doesn't support javascript.
loading
Analysis of PD-1/PD-L1 variations in lung cancer and association with immunotherapeutic efficacy and prognosis: A nonrandomized controlled trial
Ma, Jun; Song, JianRui; Han, LiNa; Zhou, Wen; Meng, LiFeng; Li, JianHui; Bai, XiaoMing.
Afiliação
  • Ma, Jun; Shanxi Provincial Peoples Hospital. Department of Thoracic Surgery. Taiyuan City. CN
  • Song, JianRui; Xian Jiaotong-Liverpool University. Wisdom Lake Academy of Pharmacy. Suzhou City. CN
  • Han, LiNa; Shanxi Medical University. Fifth Clinical Medical College. Shanxi Provincial Peoples Hospital. Taiyuan City. CN
  • Zhou, Wen; Shanxi Provincial Peoples Hospital. Department of Thoracic Surgery. Taiyuan City. CN
  • Meng, LiFeng; Shanxi Provincial Peoples Hospital. Department of Thoracic Surgery. Taiyuan City. CN
  • Li, JianHui; Shanxi Provincial Peoples Hospital. Department of Thoracic Surgery. Taiyuan City. CN
  • Bai, XiaoMing; Shanxi Provincial Peoples Hospital. Department of Thoracic Surgery. Taiyuan City. CN
Clinics ; 79: 100395, 2024. tab, graf
Article em En | LILACS-Express | LILACS | ID: biblio-1564373
Biblioteca responsável: BR1.1
ABSTRACT
Abstract Introduction This study aims to explore Programmed Death Receptor-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) variations in Lung Cancer (LC) tissues and Peripheral Blood (PPB) and their association with immunotherapy efficacy and prognosis. Method 72 patients with LC were included in the LC group and 39 patients with concurrent benign lung disease were included in the benign group. PD-1/PDL-1 was compared in PPB and lung tissue. All LC patients were treated with immunotherapy. The relationship between PD-1/PDL-1 in LC tissue and PPB and immunotherapy efficacy was analyzed. Patients were divided into death and survival groups, and PD-1/PDL-1 in tumor tissues and PPB were compared. Results The authors found that PD-1 and PDL-1 positive expression in lung tissue and PPB in LC patients was elevated. Combined detection of PD-1 and PDL-1 was effective in diagnosing LC and evaluating the prognosis of LC patients. PD-1 and PDL-1 positive expression was reduced after disease remission while elevated in dead patients. The 3-year survival rate of patients with PD-1 positive expression was 45.45 % (25/55), which was lower (82.35 %, 14/17) than those with PD-1 negative expression. The 3-year survival rate of patients with positive and negative expression of PDL-1 was 48.78 % (20/41) and 61.29 % (19/31), respectively. Discussion The present results demonstrated that PD-1 and PDL-1 are abnormal in cancer tissue and PPB of LC patients. The combined detection of PD-1 and PDL-1 has diagnostic value for LC and evaluation value for the efficacy and prognosis of immunotherapy.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Idioma: En Revista: Clinics Assunto da revista: MEDICINA Ano de publicação: 2024 Tipo de documento: Article / Project document País de afiliação: China País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Idioma: En Revista: Clinics Assunto da revista: MEDICINA Ano de publicação: 2024 Tipo de documento: Article / Project document País de afiliação: China País de publicação: Brasil